Sacituzumab govitecan-hziy Injection

Sacituzumab govitecan-hziy can cause severe or life-threatening decrease in the number of white blood cells in your blood. Your doctor will order laboratory tests regularly during your treatment to check the number of white blood cells in your blood. A decrease in the number of white blood cells in your body may increase the risk that you will develop a serious infection. If you experience any of the following symptoms, call your doctor immediately: fever, chills, sore throat, shortness of breath, ongoing cough, congestion, burning or pain when you urinate, or other signs of infection.

Sacituzumab govitecan-hziy can cause severe diarrhea. If you experience any of the following symptoms, call your doctor immediately: loose stools; diarrhea; black or bloody stools; signs of dehydration such as lightheadedness, dizziness, or faintness; or if you are unable to take fluids by mouth due to nausea or vomiting. Talk to your doctor about what you should do if you develop diarrhea at any time during your treatment with sacituzumab govitecan-hziy or if it is not controlled within 24 hours after treatment with medications for diarrhea.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests before and during your treatment to check your body’s response to sacituzumab govitecan-hziy.

Talk to your doctor about the risks of receiving sacituzumab govitecan-hziy.

🔔 Why is this medication prescribed?

Sacituzumab govitecan-hziy is used to treat ertain types of breast cancer in adults that has spread to other parts of the body or cannot be removed by surgery and who have already been treated with at least two other chemotherapy medications. Sacituzumab govitecan-hziy is also used to treat certain types of urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) in adults that has spread to other parts of the body or cannot be removed by surgery and who have already been treated with at least two other chemotherapy medications. Sacituzumab govitecan-hziy is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.

🔔 How should this medicine be used?

Sacituzumab govitecan-hziy comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 1 to 3 hours by a doctor or nurse in a hospital or medical facility. It is usually given on days 1 and 8 of a 21-day cycle. The cycle may be repeated as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and any side effects that you experience.

Pre-tax flexible spending accounts (FSAs) are often touted as the answer to high out-of-pocket medical costs, but many FSAs have “use it or lose it” rules. FSA holders lose $50 to $100 per year on average, CBS News reported, but since you’re allowed to contribute up to $2,650, you could risk losing thousands of dollars if you don’t spend your FSA money in time.

See also  Metronidazole Vaginal

Sacituzumab govitecan-hziy injection may cause infusion-related reactions, nausea, vomiting, and serious allergic reactions, which usually occur during the infusion of the medication or within 24 hours of receiving a dose. You will be given other medications to help prevent and treat reactions. A doctor or nurse will watch you carefully during and for at least 30 minutes after the infusion for any reactions to the medication. If you experience any of the following symptoms, tell your doctor immediately: nausea; vomiting; diarrhea; stomach cramps; increased salivation; swelling of your face, lips, tongue, or throat; fever; dizziness; flushing; chills; rash; hives; itching; wheezing; or difficulty breathing.

Your doctor may decrease your dose or temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with sacituzumab govitecan-hziy.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.